•Worldwide revenue declined 11 percent to $5.443 billion, driven by Zyprexa patent expirations.
•Cymbalta revenue increased 16 percent due to continued growth in both the U.S. and international markets.
•Third-quarter earnings per share were $1.18 (reported), or $0.79 (non-GAAP, when excluding income from Amylin payment and asset impairment and restructuring charge).
•Data read-outs provided a better understanding of several potential new medicines in Lilly's clinical pipeline.
•2012 non-GAAP EPS guidance reconfirmed to be in the range of $3.30 - $3.40, while reported EPS guidance range revised to $3.68 - $3.78.
Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2012.